Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome

Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome

<p>Abstract</p> <p>Background</p> <p>Different molecular therapies like the EGFR-inhibiting antibody cetuximab have come into clinical practice. Cetuximab is EMEA-approved for metastatic colorectal cancer and advanced squamous-cell head and neck cancer. Administration i...

Full description

Bibliographic Details
Main Authors: Türtscher Martina, Offner Felix, Lang Alois, Ammann Karlheinz, Haid Anton, Knauer Michael, Cerkl Peter, Wenzl Etienne
Format: Article
Language:English
Published: BMC 2007-10-01
Series:World Journal of Surgical Oncology
Online Access:http://www.wjso.com/content/5/1/114

Internet

http://www.wjso.com/content/5/1/114

Similar Items